ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 240 CHF | +1.35% |
|
+0.84% | -8.19% |
| Apr. 26 | Roche: positive CHMP opinion for Alecensa | CF |
| Apr. 26 | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
ETFs positioned on Roche Holding AG
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.06% | 2 M€ | +9.19% | - | |
| 2.06% | 2 M€ | -.--% | - | |
| 0.43% | 18 M€ | +3.79% | - | |
| 0.38% | 0 M€ | 0.00% | - | |
| 0.36% | 121 M€ | -.--% | - | |
| 0.22% | 2 M€ | -.--% | ||
| 0.13% | 6 M€ | -.--% | - | |
| 0.09% | 6 M€ | -.--% | ||
| 0.08% | 31 M€ | +3.50% | - | |
| 0.07% | 389 M€ | +6.83% | - | |
| 0.07% | 3 M€ | +9.95% | - | |
| 0.07% | 34 M€ | +6.71% | - | |
| 0.06% | 108 M€ | +2.03% | - | |
| 0.06% | 302 M€ | +3.80% | - | |
| 0.06% | 39 M€ | +3.67% | - | |
| 0.05% | 10 M€ | -3.35% | - | |
| 0.05% | 52 M€ | -0.60% | - | |
| 0.03% | 17 M€ | +1.44% | - | |
| 0.02% | 23 M€ | -.--% | - | |
| 0.02% | 786 M€ | -.--% | ||
| 0.02% | 273 M€ | +15.83% | ||
| 0.02% | 284 M€ | -.--% | ||
| 0.02% | 206 M€ | -.--% | ||
| 0.02% | 607 M€ | +0.05% | - | |
| 0.02% | 1,166 M€ | +0.26% | - | |
| 0.02% | 8 M€ | -0.60% | - |
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
221
CHF
Average target price
279.4
CHF
Spread / Average Target
+26.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -6.26% | 145B | |
| -11.77% | 144B |
- Stock Market
- Equities
- ROG Stock
- RO Stock
- Funds and ETFs Roche Holding AG
